Table 2.

Association between statin exposure and risk of MPN based on the duration of statin exposure

Subgroup	Cases, n	Controls, n	OR∗ (95% CI)	aOR† (95% CI)
Exposure
Never-use	2484	12691	1.0 (reference)	1.0 (reference)
Ever-use	1332	6389	1.07 (0.99-1.16)	0.87 (0.80-0.96)
Long-term use (≥5 y)	658	3623	0.90 (0.81-1.00)	0.72 (0.64-0.81)
Cumulative treatment duration, y
<1	211	741	1.47 (1.25-1.72)	1.15 (0.97-1.36)
1-4.99	463	2025	1.17 (1.05-1.31)	0.96 (0.85-1.08)
5-9.99	369	1862	1.02 (0.90-1.15)	0.83 (0.72-0.95)
≥10	289	1761	0.83 (0.73-0.96)	0.63 (0.54-0.74)

^∗Adjusted for age, sex, and calendar time (by matching design).

^†Adjusted for parameters denoted by ∗ in addition to (1) education level (primary school, high school, short/intermediate education, or long education); (2) Charlson Comorbidity Index (0, 1, or ≥2); (3) previous use of aspirin, other nonsteroidal anti-inflammatory drugs, alendronate, immunosuppressants, and metformin; and (4) previous history of alcohol-related diagnoses, overweight- and obesity-related diagnoses, chronic obstructive pulmonary disease, AD, and diabetes.